Biotechnology

VitroVivo Biotech LLC Highlights Tissue Analysis Capabilities for Biomedical Researchers Through Specialized Laboratory Services

October 22, 2026 2:50 AM

VitroVivo Biotech LLC, a Maryland-based provider of histology and molecular histopathology services, is highlighting its laboratory capabilities for researchers requiring detailed tissue examination, specialized cell isolation, and reliable specimen preparation. The company's service portfolio combines established histological procedures with advanced techniques used to investigate biological structures at the cellular and molecular levels....

Read more

Alligator Bioscience AB Reports Financial Results for The Period 1 January - 30 September 2026 and Provides a Business Update

October 22, 2026 2:20 AM

Alligator Bioscience (NASDAQ Stockholm:ATORX), a biotechnology company whose principal value driver is a financial interest in the HER2-targeting antibody programme HLX22, today announced its interim results for the third quarter of 2026 and provided a business update. "During the third quarter we refocused Alligator on its financial interest in HLX22, which is in global Phase 3 development at no development cost to Alligator, and carried out a...

Read more

eXoZymes CEO to Discuss Commercialization, Key Milestones, and Potential Catalysts in Fireside Chat with Water Tower Research

October 21, 2026 4:30 PM

Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that transform abundant feedstock into valuable nutraceuticals and novel medicines - announced that Chief Executive Officer, Michael Heltzen, will participate in a fireside chat hosted by Water Tower Research ("WTR") tomorrow, Thursday, October 22, 2026, at 11AM Eastern / 8AM Pacific Time. Moderated by Robert Sassoon, Managing Director of Healthcare, Emerging...

Read more

enVVeno Medical Releases New Episode of "WTF" Video Series Featuring CEO Rob Berman

October 21, 2026 8:44 AM

enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno Medical" or the "Company"), today announced the release of the third episode of its video series, "WTF with Rob Berman". The series gives investors real answers to what they need to know about enVVeno medical and why they need to know it. In the new episode, Rob Berman, CEO of enVVeno Medical, breaks down the total addressable market (TAM) for severe deep venous insufficiency (DVI), a condition...

Read more

Edison Oncology Appoints Michael Faber to Board of Directors and Announces Five Poster Presentations at Two Peer-Reviewed Oncology Meetings in November 2026

October 20, 2026 9:00 AM

Edison Oncology Holding Corp. ("Edison Oncology" or the "Company"), a clinical-stage biopharmaceutical company focused on developing innovative small-molecule therapies by unlocking the potential of existing drugs and compounds for genetically defined cancers, today announced the appointment of Michael Faber to its Board of Directors. The Company also announced that five abstracts have been accepted for presentation at the 31st Annual Meeting of...

Read more

Lobe Sciences Appoints Tracy L. Goeken, M.D., as Chief Medical Officer

October 20, 2026 8:30 AM

Lobe Sciences Ltd. ("Lobe" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F), a clinical-stage biopharmaceutical company developing therapies for neurological conditions and rare diseases, today announced the appointment of Tracy L. Goeken, M.D., as Chief Medical Officer, effective October 20, 2026. Dr. Goeken most recently served as Chief Medical Officer at Linical, a global clinical research organization, where he led clinical development...

Read more

RMTG to Go Ringside at BKFC This Weekend to Capture Content for Its "RMTG Brief" Investor-Awareness Campaign

October 20, 2026 7:01 AM

Regenerative Medical Technology Group Inc. (the "Company" or "RMTG") (OTCID:RMTG), a regenerative medicine company operating through its wholly owned subsidiary Global Stem Cells Group, today announced that its content team will be ringside at this Saturday's Bare Knuckle Fighting Championship (BKFC) event to capture footage for "RMTG Brief," the Company's host-led investor-awareness and brand-visibility campaign. The on-site shoot is the latest...

Read more

Microbix Attending & Presenting at IPVS 2026

October 19, 2026 7:00 AM

Microbix Biosystems Inc. (TSX:MBX)(OTCQX:MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that it will be attending IPVS 2026 and presenting results of a novel synthetic vaginal matrix designed to assist with validation and ongoing quality management of HPV molecular assays used in cervical cancer screening programs. IPVS 2026 is the 38th annual conference of the International Papillomavirus Society, taking...

Read more

Faron to Report Final Melanoma Survival Data from the MATINS Study at ESMO 2026

October 19, 2026 2:30 AM

Faron Pharmaceuticals Ltd. (HEL:FARON)(LSE:FARN), a global, clinical-stage biopharmaceutical company focused on creating innovative cancer treatments that leverage the patient's own immune system, today announces that final results from the metastatic melanoma cohort of its Phase 1/2 MATINS study have been accepted as an ePoster at the European Society for Medical Oncology (ESMO) Congress 2026, taking place in Madrid, Spain, 23-27 October 2026....

Read more

BioInvent To Present BI-1808 Data in Platinum-Resistant Recurrent Ovarian Cancer at ESMO 2026

October 18, 2026 6:40 PM

BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a leader in the discovery of novel immunomodulatory antibodies, today announced the publication of an abstract ahead of its poster presentation at the ESMO Congress 2026 (European Society for Medical Oncology) in Madrid, October 23-27. The abstract reports previously communicated Phase 1/2a data (ASCO 2026) for BI-1808, a first-in-class anti-TNFR2 antibody, combined with MSD's...

Read more

AI Maverick Intel Signs Definitive Agreement to Acquire Heal Access, an Agentic AI Healthcare Platform

October 15, 2026 1:00 PM

AI Maverick Intel, Inc. (OTCID:AIMV) ("AIMV" or the "Company") has entered into a definitive share purchase agreement (the "Share Purchase Agreement") to acquire, through a wholly owned subsidiary, all of the issued and outstanding shares of Heal Access Canada Inc. ("Heal Access") from HEAL Group Holdings Inc. ("HEAL Group"), AIMV's controlling stockholder. The Share Purchase Agreement follows the non-binding letter of intent announced on March...

Read more

BioInvent Announces Publication of First-in-Human BI-1808 Data in Clinical Cancer Research

October 15, 2026 10:20 AM

BioInvent International (STO:BINV) - BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a leader in discovering novel immune-modulatory antibodies, today announced the publication of results from the first-in-human Phase 1 study of the BI-1808 antibody in Clinical Cancer Research, a journal of the American Association for Cancer Research (AACR). BI-1808 binds to TNFR2 and is the first antibody in its class to be tested in...

Read more

Xenetic Biosciences and PeriNess Announce First Patient Dosed in Investigator-Initiated Study at Tel Aviv Sourasky University Medical Center Evaluating Systemic DNase in Combination with CAR T Cells for Large B-Cell Lymphoma

October 15, 2026 8:46 AM

Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today announced that its collaboration partner, PeriNess Ltd. ("PeriNess"), has informed the Company that the first patient has been dosed in an investigator-initiated clinical study evaluating systemic recombinant human DNase in combination with...

Read more

Invitation to Alligator Bioscience's Interim Report Call on 22 October 2026

October 15, 2026 8:20 AM

Alligator Bioscience (Nasdaq Stockholm:ATORX), a biotechnology company whose principal asset is a financial interest in the HER2-targeting antibody programme HLX22, will publish its interim report for July - September 2026 on Thursday, 22 October 2026, at 8:00 a.m. CEST. On the same day, Alligator will host a webinar and conference call for investors, analysts and media at 2:00 p.m. CEST / 8:00 a.m. EDT, where CEO Søren Bregenholt and CFO Johan...

Read more

Bio Essence Corporation Expands MediFlow Platform with Development of Practitioner-Specific AI and RAG Technology

October 15, 2026 8:00 AM

Bio Essence Corporation (OTCQB:BIOE) ("Bio Essence" or the "Company") today announced that it has entered into a technology development agreement with Zhituo Software Co., Limited ("Zhituo") to develop and integrate practitioner-focused artificial intelligence and retrieval-augmented generation ("RAG") capabilities into Bio Essence's MediFlow platform. The initiative is designed to enable authorized healthcare and wellness practitioners to...

Read more

Vetagro Opens Its First U.S. Manufacturing Facility in Easton, Maryland

October 15, 2026 7:35 AM

Vetagro, an international group with Italian roots that specializes in precision animal nutrition, today officially opened its first manufacturing facility in the United States. The new 40,000-square-foot production and distribution plant was built on a 14-acre property at Mistletoe Hall Business Park in Easton, Maryland. The new plant will expand Vetagro's production capacity and bring its supply chain closer to North American customers, while...

Read more

ClearPoint Neuro to Announce Third Quarter 2026 Results October 28, 2026

October 14, 2026 4:05 PM

ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that it will release financial results for its 2026 third quarter on Wednesday, October 28, 2026, after the market close. Investors and analysts are invited to listen to the live broadcast review of the Company's 2026 third quarter on Wednesday, October 28 at 4:30 p.m....

Read more

Ablexis Announce License Agreement with Novo

October 14, 2026 8:00 AM

Ablexis, LLC, a biopharmaceutical company focused on advancing human antibody drug discovery through provision of its AlivaMab® Mouse technology, announced today an agreement granting Novo Nordisk A/S (Novo) a non-exclusive license to Ablexis' proprietary AlivaMab Mouse human antibody drug discovery platforms to discover, develop, and commercialize biologics drugs comprising AlivaMab antibodies. The license provides Novo rights to possess and...

Read more

Lobe Sciences Appoints Annette Grimaldi, Former Head of Life Sciences Investment Banking at BMO Capital Markets, to Board of Directors

October 14, 2026 8:00 AM

Lobe Sciences Ltd. ("Lobe Sciences" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F), a clinical-stage biopharmaceutical company focused on advancing therapies for diseases with significant unmet medical needs, today announced the appointment of Annette Grimaldi to its Board of Directors. Ms. Grimaldi is a veteran life sciences investment banker with 35 years of experience advising CEOs, CFOs and boards on public and private financings,...

Read more

Partillion Nanovials to Support $2.5M CIRM-Funded Study of CAR T Cell Potency

October 14, 2026 7:15 AM

Partillion Bioscience today announced that its Nanovial technology will be used in a USC-led research project supported by a $2.5 million California Institute for Regenerative Medicine (CIRM) Discovery Award. The project is led by Mohamed Abou-el-Enein, M.D., Ph.D., of the USC Keck School of Medicine. CAR T therapies have transformed treatment for several blood cancers and are increasingly being investigated for autoimmune disease. Yet...

Read more